News | December 26, 2007

National Cancer Institute Approves Roswell Park’s Core Grant For Five Years

December 27, 2007 - Roswell Park Cancer Institute’s (RPCI) Cancer Center Support Grant (CCSG) will be renewed by the National Cancer Institute (NCI) for five years, following the receipt of the best CCSG score in its history.

RPCI has been an NCI-designated comprehensive cancer center, without interruption, since 1974, and was one of the three centers used by the NCI as a model for the 39 comprehensive cancer centers in existence today.

"The receipt of a superb score on the renewal of our NCI Core Grant is testament to the outstanding work of the Roswell Park team and affirms that we are committed to conducting innovative and pioneering research and providing exemplary patient care," said Donald L. Trump , M.D., FACP, President & CEO, RPCI. "These are the attributes of a world class cancer center and we are proud that the NCI has recognized the quality of our cancer programs and faculty."

To be designated a comprehensive cancer center by the National Cancer Institute, a cancer center must demonstrate depth and breadth of research activities in each of the three major areas of cancer research including basic; clinical; and prevention, control and population-based research, as well as maintain a strong body of interactive research that bridges these scientific areas.

In the area of clinical research, a comprehensive cancer center must initiate and conduct early phase, innovative clinical trials; and provide leadership and accrue patients to these trials. A center also must provide outreach, education and information on cancer to the community it serves.

The CCSG renewal is a multi-step competitive process. RPCI's renewal involved submitting a 1,100 page comprehensive grant application and an on-site visit in September 2007 from NCI peer-reviewers. After a thorough and rigorous review, RPCI's scores improved in more than 25 areas when compared to its last review in 2003 and are among the best scores the institute has ever received.

For more information:

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init